AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
白云追月素
发表于 2024-6-26 15:13:22
263
0
0
AstraZeneca announced on June 26 that the National Medical Products Administration of China officially approved Teresa& on June 18, 2024; reg; The combination of pemetrexed and platinum based chemotherapy drugs is used as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutation.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Innovation Drug Enterprises on the Science and Technology Innovation Board Welcoming a Harvest Year: Baekje Shenzhou PD-1 New Indications Accepted by FDA
- JAK1 inhibitor Xibico? New indications for age expansion approved in China
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Dialogue with Qian Jing, Vice President of Jingke Energy: Market oriented ability is crucial for the third and fourth quarters of the industry to show signs of recovery
- AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
- Incidence rate of lung cancer death in women is higher than that in men
- The bladder cancer targeting drug erdafitinib of Johnson&Johnson was approved in the EU
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
